Lexicon Pharmaceuticals (LXRX) Operating Leases (2022 - 2024)

Lexicon Pharmaceuticals (LXRX) has 3 years of Operating Leases data on file, last reported at $6.4 million in Q1 2024.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $6.4 million in Q1 2024; TTM through Mar 2024 was $6.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $5.3 million, down 2.93% from the prior year.
• Operating Leases for Q1 2024 stood at $6.4 million, up from $5.3 million in the prior quarter.
• Over the last five years, Operating Leases for LXRX reached as high as $6.4 million in Q1 2024 and fell as low as $5.3 million in Q4 2023.
• Historically, Operating Leases has averaged $5.6 million across 3 years, with a median of $5.4 million in 2022.
• On a YoY basis, Operating Leases climbed as much as 2.93% in 2023 and fell as far as 2.93% in 2023.
• Year by year, Operating Leases stood at $5.4 million in 2022, then slipped by 2.93% to $5.3 million in 2023, then advanced by 20.99% to $6.4 million in 2024.
• Per Business Quant data, the three most recent Operating Leases figures were $6.4 million in Q1 2024, $5.3 million in Q4 2023, and $5.4 million in Q3 2023.